MiRNA-155 and colorectal cancer, the role of real time PCR in laboratory diagnosis

Amongst the biomolecules currently used for laboratory diagnosis in colorectal cancer (CRC),many have been shown to be insufficient for predicting prognosis in the critical stages of the disease. This is still the case today even though significant advances have been made in early diagnosis and therapeutic strategies, e.g. with extensive SNP analysis in oncogenes. CRC still draws great attention throughout the world because of its high incidence rate and mortality. At the moment, specific and selective diagnosis by optimal molecular biomarkers is of utmost necessity in patients with poor prognosis, because of the extremely low therapeutic potential and the need for a fast response to a possible individualized target therapy.